Impact of Tissue Plasminogen Activator Dosing on Patients Weighing More Than 100  kg on 3-Month Outcomes in Acute Ischemic Stroke

The landmark National Institute of Neurological Disorders and Stroke (NINDS) tissue plasminogen activator (tPA) trial established the effectiveness and dosing of intravenous tPA for acute ischemic stroke (AIS) at .9  mg/kg with a maximum dose of 90 mg. Since the publication of the NINDS trial in 1995, there has been a drastic increase in the amount of obesity and the average weight of adults in the United States, which has caused an increase in the number of patients receiving 90 mg of alteplase for AIS.
Source: Journal of Stroke and Cerebrovascular Diseases - Category: Neurology Authors: Source Type: research